Inactive Instrument

Loon Energy Corporation Toronto S.E.

Equities

LNE.H

CA5435123057

Biotechnology & Medical Research

Loon Energy Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022

May 12, 2022 at 09:48 am EDT

Loon Energy Corporation reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 0.012863 million compared to USD 0.053972 million a year ago.

Latest news about Loon Energy Corporation

Optimind Pharma Reaches Agreement On Debenture Conversion	Jan. 26	MT
Optimind Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	Jan. 10	CI
Optimind Pharma Corp. Announces Executive Changes	Jan. 08	CI
Optimind Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-30	CI
Optimind Pharma Corp. Reports Earnings Results for the First Quarter Ended May 31, 2023	23-07-28	CI
Optimind Pharma Corp. Auditor Raises 'Going Concern' Doubt	23-06-27	CI
Optimind Pharma Corp. Reports Earnings Results for the Full Year Ended February 28, 2023	23-06-27	CI
Optimind Pharma Corp. acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.	22-09-19	CI
Optimind Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Optimind Pharma Corp. Provides Update on Health Canada's Dealer License Under Joint-Venture with Manitari Pharma Corporation	22-08-10	CI
Optimind Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-08-03	CI
Optimind Pharma Inc. completed the acquisition of Loon Energy Corporation (TSXV:LNE.H) in a reverse merger transaction.	22-07-27	CI
Optimind Pharma Corp. announced that it has received CAD 0.507 million in funding	22-04-03	CI
Optimind Pharma Inc. entered into a letter of intent to acquire Loon Energy Corporation (TSXV:LNE.H) for CAD 8.3 million in a reverse merger transaction.	21-11-15	CI

Chart Loon Energy Corporation

Duration

Period

More charts

Company Profile

Optimind Pharma Corp. is a Canada-based emerging provider of psychedelic therapies for the masses. The Company helps people suffering from post-traumatic stress disorder (PTSD), anxiety, depression and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. The Company also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings. Its treatment programs are designed based on scientific research and specific modalities used in many different therapeutic practices. Each treatment program combines the use of psychedelic medicine with therapeutic processing and integration. It has two different types of treatments. Monotherapy and assisted therapy, all based on a Ketamine capsule. The effects are felt about 30 minutes after, and within two hours of taking the medicine, cognition is resorted to normal.

Sector

Biotechnology & Medical Research

Calendar

2024-06-26 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs